Investment Analysts’ Recent Ratings Updates for CRISPR Therapeutics (CRSP)

A number of firms have modified their ratings and price targets on shares of CRISPR Therapeutics (NASDAQ: CRSP) recently:

• 2/13/2026 – CRISPR Therapeutics had its “outperform” rating reaffirmed by analysts at Evercore ISI.
• 2/13/2026 – CRISPR Therapeutics had its “hold” rating reaffirmed by analysts at TD Cowen. They now have a $45.00 price target on the stock, up previously from $40.00.
• 2/13/2026 – CRISPR Therapeutics had its price target raised by analysts at Needham & Company LLC from $80.00 to $82.00. They now have a “buy” rating on the stock.
• 1/30/2026 – CRISPR Therapeutics had its “market outperform” rating reaffirmed by analysts at Citigroup Inc..
• 1/30/2026 – CRISPR Therapeutics had its price target lowered by analysts at Citizens Jmp from $86.00 to $80.00. They now have a “market outperform” rating on the stock.
• 1/22/2026 – CRISPR Therapeutics had its price target lowered by analysts at Bank of America Corporation from $90.00 to $89.00. They now have a “buy” rating on the stock.
• 1/21/2026 – CRISPR Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/23/2025 – CRISPR Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $80.00 price target on the stock.
• 12/23/2025 – CRISPR Therapeutics had its “market outperform” rating reaffirmed by analysts at Citizens Jmp. They now have a $86.00 price target on the stock.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 60,000 shares of the firm’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $60.23, for a total value of $3,613,800.00. Following the completion of the sale, the chief executive officer owned 134,201 shares of the company’s stock, valued at $8,082,926.23. This trade represents a 30.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 4.30% of the stock is currently owned by corporate insiders.

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.